BridgeBio Oncology Therapeutics, Inc. Interest Income, Operating
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Interest Income, Operating of $3.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOperating · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. interest income, operating for the quarter ending 2026-06-30 was $3.55M, a 113.15% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. interest income, operating for the quarter ending 2026-03-31 was $3.94M, a 118.02% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. interest income, operating for the quarter ending 2025-12-31 was $4.42M, a 107.41% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. interest income, operating for the quarter ending 2025-09-30 was $3.44M, a 39.26% increase year-over-year.
| Period end | Interest Income, Operating 3 month | Interest Income, Operating 6 month | Interest Income, Operating 9 month | Interest Income, Operating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.55M 10-Q · filed 2026-08-11 | $7.50M 10-Q · filed 2026-08-11 | $11.92M derived: sum of 3 quarters · filed 2026-08-11 | $15.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.94M 10-Q · filed 2026-05-12 | $8.37M derived: sum of 2 quarters · filed 2026-05-12 | $11.81M derived: sum of 3 quarters · filed 2026-05-12 | $13.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.42M 8-K · filed 2026-03-05 | $7.87M derived: sum of 2 quarters · filed 2026-03-05 | $9.53M derived: sum of 3 quarters · filed 2026-08-11 | $11.34M POS AM · filed 2026-04-30 |
| 2025-09-30 | $3.44M 10-Q · filed 2025-11-12 | $5.11M derived: sum of 2 quarters · filed 2026-08-11 | $6.92M 10-Q · filed 2025-11-12 | $9.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.67M 10-Q · filed 2026-08-11 | $3.48M 10-Q · filed 2026-08-11 | $5.61M derived: sum of 3 quarters · filed 2026-08-11 | $8.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.81M 10-Q · filed 2026-05-12 | $3.94M derived: sum of 2 quarters · filed 2026-05-12 | $6.42M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $2.13M 8-K · filed 2026-03-05 | $4.61M derived: sum of 2 quarters · filed 2026-03-05 | $6.38M POS AM · filed 2026-04-30 | |
| 2024-09-30 | $2.47M 10-Q · filed 2025-11-12 | $4.24M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |